Merck (MRK) Common Equity (2009 - 2026)
Merck (MRK) posted quarterly Common Equity of $109.6 billion for Q1 2026, up 126.5% year-over-year from $48.4 billion in Q1 2025, and up 108.39% quarter-over-quarter from $52.6 billion in Q4 2025.
Merck (MRK) Common Equity (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Common Equity for 18 consecutive years, with $109.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 126.5% year-over-year to $109.6 billion; the TTM figure through Mar 2026 stood at $109.6 billion (up 126.5% YoY), while the FY2025 annual figure was $52.6 billion, up 13.44% from the prior year.
- Common Equity advanced to $109.6 billion in Q1 2026 per MRK's latest filing, from $52.6 billion in the prior quarter.
- Across five years, Common Equity topped out at $113.6 billion in Q3 2025 and bottomed at $37.6 billion in Q4 2023.
- Historically, Common Equity has averaged $52.2 billion across 5 years, with a median of $44.6 billion in 2024.
- Annual changes were most pronounced in 2023 — Common Equity decreased 18.29% — and 2025, when it jumped 155.05%.
- Merck's Common Equity stood at $46.1 billion in 2022, then retreated by 18.29% to $37.6 billion in 2023, then increased by 23.22% to $46.4 billion in 2024, then climbed by 13.44% to $52.6 billion in 2025, then jumped by 108.39% to $109.6 billion in 2026.
- Business Quant data shows MRK's Common Equity at $109.6 billion in Q1 2026, $52.6 billion in Q4 2025, and $113.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.87 Bn | 633.12 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.41 Bn | 463.84 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 303.87 Bn | 296.18 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.75 Bn | 252.85 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 236.40 Bn | 222.41 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 182.11 Bn | 178.93 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 159.54 Bn | 147.84 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 106.30 Bn | 102.13 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn | 80.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106.07 Bn |
| Mar 31, 2026 | 109.63 Bn |
| Dec 31, 2025 | 52.61 Bn |
| Sep 30, 2025 | 113.65 Bn |
| Jun 30, 2025 | 49.06 Bn |
| Mar 31, 2025 | 48.40 Bn |
| Dec 31, 2024 | 46.37 Bn |
| Sep 30, 2024 | 44.56 Bn |
| Jun 30, 2024 | 43.65 Bn |
| Mar 31, 2024 | 40.42 Bn |
| Dec 31, 2023 | 37.64 Bn |
| Sep 30, 2023 | 41.30 Bn |
| Jun 30, 2023 | 38.74 Bn |
| Mar 31, 2023 | 46.91 Bn |
| Dec 31, 2022 | 46.06 Bn |
| Sep 30, 2022 | 44.52 Bn |
| Jun 30, 2022 | 43.32 Bn |
| Mar 31, 2022 | 40.95 Bn |
| Dec 31, 2021 | 38.26 Bn |
| Sep 30, 2021 | 35.86 Bn |